About ProMetic BioSciences Ltd
Using its unique and proprietary Mimetic Ligand(TM) technology, ProMetic BioSciences Ltd ("PBL") specializes in the development and manufacture of robust affinity separation materials which provide very high levels of purification. This is achieved by use of small chemical affinity ligands designed to bind a target biomolecule specifically and reversibly. In view of their use for the production of therapeutics, ProMetic's affinity products are manufactured according to a strict quality system based on good manufacturing practice at PBL's ISO 9001:2000 certified manufacturing facility on the Isle of Man, which completed a (pnds stlg)1.5 million expansion in 2005. PBL also operates an R&D laboratory located on the Cambridge Science Park, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our
current expectations about the markets we operate in and on various
estimates and assumptions. Actual events or results may differ materially
from those anticipated in these forward-looking statements if known or
unknown risks affect our business, or if our estimates or assumptions turn
out to be inaccurate. Such risks and assumptions include, but are not
limited to, ProMetic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of ProMetic to take advantage
of business opportunities in the pharmaceutical industry, uncertainties
related to t
|SOURCE PROMETIC LIFE SCIENCES INC.|
Copyright©2008 PR Newswire.
All rights reserved